RS53956B1 - Novi polimorf - Google Patents
Novi polimorfInfo
- Publication number
- RS53956B1 RS53956B1 RS20150258A RSP20150258A RS53956B1 RS 53956 B1 RS53956 B1 RS 53956B1 RS 20150258 A RS20150258 A RS 20150258A RS P20150258 A RSP20150258 A RS P20150258A RS 53956 B1 RS53956 B1 RS 53956B1
- Authority
- RS
- Serbia
- Prior art keywords
- solid form
- ylcarbonyl
- tetrahydro
- benzazepin
- proline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1005623.2A GB201005623D0 (en) | 2010-04-01 | 2010-04-01 | New polymorph |
| US34704810P | 2010-05-21 | 2010-05-21 | |
| PCT/GB2011/000500 WO2011121308A1 (en) | 2010-04-01 | 2011-03-31 | New polymorph |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS53956B1 true RS53956B1 (sr) | 2015-08-31 |
Family
ID=42228830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20150258A RS53956B1 (sr) | 2010-04-01 | 2011-03-31 | Novi polimorf |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9079881B2 (enExample) |
| EP (1) | EP2552910B1 (enExample) |
| JP (1) | JP5802737B2 (enExample) |
| KR (1) | KR101792621B1 (enExample) |
| CN (1) | CN102918038B (enExample) |
| CA (1) | CA2795109C (enExample) |
| DK (1) | DK2552910T3 (enExample) |
| ES (1) | ES2538085T3 (enExample) |
| GB (1) | GB201005623D0 (enExample) |
| HR (1) | HRP20150513T1 (enExample) |
| HU (1) | HUE026442T2 (enExample) |
| ME (1) | ME02102B (enExample) |
| MX (1) | MX2012011382A (enExample) |
| PL (1) | PL2552910T3 (enExample) |
| PT (1) | PT2552910E (enExample) |
| RS (1) | RS53956B1 (enExample) |
| RU (1) | RU2559633C2 (enExample) |
| SI (1) | SI2552910T1 (enExample) |
| SM (1) | SMT201500107B (enExample) |
| WO (1) | WO2011121308A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201105537D0 (en) | 2011-03-31 | 2011-05-18 | Vantia Ltd | New process |
| CN104059070B (zh) * | 2013-09-17 | 2016-02-10 | 天津药物研究院有限公司 | 利希普坦晶型ⅰ及其制备方法和用途 |
| CN103755707B (zh) * | 2013-09-17 | 2015-11-18 | 天津药物研究院 | 利希普坦晶型ⅱ及其制备方法和用途 |
| CN103694240B (zh) * | 2013-09-18 | 2015-11-18 | 天津药物研究院 | 利希普坦的溶剂合物及其制备方法和用途 |
| CN104140429B (zh) * | 2014-07-25 | 2015-11-18 | 天津药物研究院 | 利希普坦晶型ⅴ及其制备方法和用途 |
| CN108026059A (zh) * | 2015-07-22 | 2018-05-11 | 阿纳韦克斯生命科学公司 | 四氢-n，n-二甲基-2，2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物 |
| WO2020154581A1 (en) | 2019-01-24 | 2020-07-30 | Assia Chemical Industries Ltd | Solid state forms of fedovapagon-salicyclic acid co-crystal |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW359669B (en) | 1995-12-15 | 1999-06-01 | Otsuka Pharma Co Ltd | Benzazepine derivatives |
| DK1000062T3 (da) | 1997-07-30 | 2004-11-22 | Wyeth Corp | Tricykliske vasopressinagonister |
| DE69826677T2 (de) | 1997-07-30 | 2005-02-10 | Wyeth | Trizyclische Vasopressin-Agonisten |
| DK1149096T3 (da) | 1999-02-04 | 2003-04-07 | Wyeth Corp | Tricykliske pyridin-N-oxider som vasopressinagonister |
| JP2002536377A (ja) | 1999-02-04 | 2002-10-29 | ワイス | バソプレシンアゴニストとしてのチエエニルベンゾイルベンズアゼピン類 |
| WO2000046225A2 (en) | 1999-02-04 | 2000-08-10 | American Home Products Corporation | Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists |
| CN1339037A (zh) | 1999-02-04 | 2002-03-06 | 美国家用产品公司 | 吡咯并苯并二吖庚因酰胺血管加压素激动剂 |
| GB0000079D0 (en) | 2000-01-05 | 2000-02-23 | Ferring Bv | Novel antidiuretic agents |
| GB0015601D0 (en) * | 2000-06-26 | 2000-08-16 | Ferring Bv | Novel antidiuretic agents |
-
2010
- 2010-04-01 GB GBGB1005623.2A patent/GB201005623D0/en not_active Ceased
-
2011
- 2011-03-31 ME MEP-2015-56A patent/ME02102B/me unknown
- 2011-03-31 HR HRP20150513TT patent/HRP20150513T1/hr unknown
- 2011-03-31 MX MX2012011382A patent/MX2012011382A/es active IP Right Grant
- 2011-03-31 SI SI201130487T patent/SI2552910T1/sl unknown
- 2011-03-31 US US13/637,873 patent/US9079881B2/en not_active Expired - Fee Related
- 2011-03-31 RU RU2012146544/04A patent/RU2559633C2/ru not_active IP Right Cessation
- 2011-03-31 CN CN201180026714.4A patent/CN102918038B/zh not_active Expired - Fee Related
- 2011-03-31 DK DK11714079T patent/DK2552910T3/en active
- 2011-03-31 RS RS20150258A patent/RS53956B1/sr unknown
- 2011-03-31 JP JP2013501934A patent/JP5802737B2/ja not_active Expired - Fee Related
- 2011-03-31 CA CA2795109A patent/CA2795109C/en not_active Expired - Fee Related
- 2011-03-31 HU HUE11714079A patent/HUE026442T2/en unknown
- 2011-03-31 EP EP11714079.8A patent/EP2552910B1/en active Active
- 2011-03-31 PT PT117140798T patent/PT2552910E/pt unknown
- 2011-03-31 WO PCT/GB2011/000500 patent/WO2011121308A1/en not_active Ceased
- 2011-03-31 KR KR1020127028111A patent/KR101792621B1/ko not_active Expired - Fee Related
- 2011-03-31 PL PL11714079T patent/PL2552910T3/pl unknown
- 2011-03-31 ES ES11714079.8T patent/ES2538085T3/es active Active
-
2015
- 2015-05-05 SM SM201500107T patent/SMT201500107B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5802737B2 (ja) | 2015-11-04 |
| CN102918038A (zh) | 2013-02-06 |
| RU2012146544A (ru) | 2014-05-10 |
| RU2559633C2 (ru) | 2015-08-10 |
| KR20130023218A (ko) | 2013-03-07 |
| US20140296213A1 (en) | 2014-10-02 |
| CN102918038B (zh) | 2015-09-09 |
| PT2552910E (pt) | 2015-05-13 |
| HUE026442T2 (en) | 2016-06-28 |
| CA2795109C (en) | 2018-04-17 |
| PL2552910T3 (pl) | 2015-07-31 |
| EP2552910A1 (en) | 2013-02-06 |
| CA2795109A1 (en) | 2011-10-06 |
| KR101792621B1 (ko) | 2017-11-02 |
| EP2552910B1 (en) | 2015-03-11 |
| JP2013523706A (ja) | 2013-06-17 |
| DK2552910T3 (en) | 2015-04-07 |
| HRP20150513T1 (hr) | 2015-06-05 |
| ES2538085T3 (es) | 2015-06-17 |
| SI2552910T1 (sl) | 2015-06-30 |
| SMT201500107B (it) | 2015-07-09 |
| GB201005623D0 (en) | 2010-05-19 |
| MX2012011382A (es) | 2013-01-29 |
| US9079881B2 (en) | 2015-07-14 |
| WO2011121308A1 (en) | 2011-10-06 |
| ME02102B (me) | 2015-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS53956B1 (sr) | Novi polimorf | |
| RU2704795C2 (ru) | Кристаллическая форма бисульфата ингибитора jak и способ ее получения | |
| RS20120339A1 (sr) | Polimorfni oblici 3-(4-amino-1-okso-1, 3-dihidro-izoindol-2-il)-piperidin-2, 6-diona | |
| JP2021527680A (ja) | Ａｒｎ−５０９の結晶形、その製造方法及びその用途 | |
| WO2018184185A1 (zh) | 奥扎莫德加成盐晶型、制备方法及药物组合物和用途 | |
| JP2025510292A (ja) | ５－ＭｅＯ－ＤＭＴの結晶性臭化水素酸塩 | |
| CA2829690C (en) | Mixed crystal agomelatine (form-viii), preparation method and use thereof and pharmaceutical composition containing same | |
| WO2015003571A1 (zh) | 达拉菲尼甲磺酸盐的新晶型及其制备方法 | |
| EP3656767A1 (en) | Beraprost-314d monohydrate crystals and methods for preparation thereof | |
| KR101903641B1 (ko) | 1-(2-메틸-4-(2,3,4,5-테트라하이드로-1-벤즈아제핀-1-일카보닐)벤질카르바모일)-l-프롤린-n,n-디메틸아미드의 제조 방법 | |
| WO2019210511A1 (zh) | 一种s1p1受体激动剂的加成盐及其晶型和药物组合物 | |
| CN105985409B (zh) | 一种卡非佐米马来酸盐结晶及其制备方法 | |
| WO2019134455A1 (zh) | Acalabrutinib的新晶型及其制备方法和用途 | |
| CN110650960A (zh) | Acalabrutinib的新晶型及其制备方法和用途 | |
| CA2949155C (en) | Allisartan isoproxil polymorph, its preparation method and pharmaceutical | |
| WO2018233678A1 (zh) | 右旋雷贝拉唑钠化合物及其药物组合物 | |
| US20110165202A1 (en) | Solid state forms of fosamprenavir calcium salt and processes for preparation thereof | |
| JP2022553706A (ja) | 低酸素誘導因子－プロリルヒドロキシラーゼ阻害剤の結晶形 | |
| EP3710425A1 (en) | Solid state forms of elafibranor | |
| WO2025035486A1 (zh) | 一种酪氨酸激酶抑制剂的可药用盐、结晶形式及其制备方法 | |
| WO2025140479A1 (zh) | Iclepertin的晶型及其制备方法和用途 | |
| WO2019011336A1 (zh) | Qaw-039的晶型及其制备方法和用途 | |
| WO2018059420A1 (zh) | E52862盐酸盐晶型h及其制备方法 | |
| WO2020001460A1 (zh) | 氮杂双环基取代的三唑类衍生物的可药用盐、晶型及制备方法 |